Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. (Q51981194)

19 April 2018

title

Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. (English)

1 reference

19 April 2018

0 references

Kimura M

1

1 reference

19 April 2018

Asada T

2

1 reference

19 April 2018

Uno M

3

1 reference

19 April 2018

Machida N

4

1 reference

19 April 2018

Kasuya K

5

1 reference

19 April 2018

Taniguchi Y

6

1 reference

19 April 2018

Fujita T

7

1 reference

19 April 2018

Nishiyama E

8

1 reference

19 April 2018

Iwamoto N

9

1 reference

19 April 2018

Arai H

10

1 reference

19 April 2018

language of work or name

English

0 references

publication date

1 October 1999

1 reference

19 April 2018

number of pages

3

1 reference

inferred from page(s)

published in

Neuroscience Letters

1 reference

19 April 2018

volume

273

1 reference

19 April 2018

issue

2

1 reference

19 April 2018

page(s)

137-139

1 reference

19 April 2018

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

Immunodetection of the amyloid P component in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

Amyloid P component promotes aggregation of Alzheimer's beta-amyloid peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

Serum amyloid P in Alzheimer's disease. Implications for dysfunction of the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

Amyloid-P-component-like immunoreactivity in beta/A4-immunoreactive deposits in Alzheimer-type dementia brains.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

Decreased α-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's diseas

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2899%2900631-X

7 January 2021

10.1016/S0304-3940(99)00631-X

Identifiers

DOI

1 reference

19 April 2018

PubMed ID

10505635

1 reference

19 April 2018